1206c5b7a3
- Source: inbox/queue/2026-05-08-exenatide-parkinsons-phase3-lancet-failure.md - Domain: health - Claims: 0, Entities: 1 - Enrichments: 2 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
56 lines
No EOL
2.8 KiB
Markdown
56 lines
No EOL
2.8 KiB
Markdown
---
|
|
type: entity
|
|
entity_type: research_program
|
|
name: Exenatide-PD3 Trial
|
|
domain: health
|
|
status: completed
|
|
---
|
|
|
|
# Exenatide-PD3 Trial
|
|
|
|
**Type:** Phase 3 randomized controlled trial
|
|
**Drug:** Exenatide (GLP-1 receptor agonist)
|
|
**Indication:** Parkinson's disease (disease-modifying therapy)
|
|
**Design:** Multicenter, double-blind, placebo-controlled, n=194, 96 weeks
|
|
**Sites:** 6 UK research hospitals
|
|
**Funding:** National Institute for Health and Care Research (NIHR)
|
|
**Primary Endpoint:** Movement symptom progression (motor function)
|
|
**Status:** Failed (February 2025)
|
|
|
|
## Overview
|
|
|
|
Exenatide-PD3 was the largest and longest GLP-1 receptor agonist trial in Parkinson's disease to date. It tested whether exenatide once-weekly could slow disease progression by providing neuroprotection to dopaminergic neurons in the substantia nigra.
|
|
|
|
## Results
|
|
|
|
**Primary endpoint:** FAILED — exenatide did not stop movement symptoms from worsening over 96 weeks versus placebo.
|
|
|
|
**Secondary endpoints:** FAILED — no benefit in non-motor symptoms (quality of life, cognition, mood) compared to placebo.
|
|
|
|
**DaT-SPECT imaging:** No significant change versus placebo. This biomarker tracks dopaminergic neuron degeneration; zero signal indicates no neuroprotection at the structural level.
|
|
|
|
**CSF analysis (mechanistic finding):** Only small amounts of exenatide reached the substantia nigra, the brain region affected by Parkinson's. This suggests insufficient CNS penetration to the target region, despite exenatide crossing the blood-brain barrier in other areas.
|
|
|
|
## Context
|
|
|
|
This trial directly contradicts earlier Phase 2 work (Foltynie group, n=59) which showed significant motor benefit at 9 months (P=0.001). The Phase 3 failure raises questions about:
|
|
- Phase 2 selection bias or underpowering
|
|
- Regional brain penetrance as the limiting factor (not BBB crossing per se)
|
|
- Whether the Phase 2 signal was spurious
|
|
|
|
## Implications
|
|
|
|
The failure complicates the GLP-1 neuroprotection hypothesis. Two other GLP-1 agonists (semaglutide, liraglutide) remain in ongoing Phase 3 trials for Parkinson's. The CSF finding suggests that different GLP-1 agonists with distinct CNS penetration mechanisms (e.g., semaglutide via albumin binding → tanycytes) may achieve different substantia nigra concentrations and potentially different outcomes.
|
|
|
|
## Expert Response
|
|
|
|
Dr. Katherine Fletcher (Parkinson's UK): "Really disappointing news" and "a setback." Concerns raised that the failure may impact funding for other GLP-1 trials in Parkinson's.
|
|
|
|
## Timeline
|
|
|
|
- **2025-02-04** — Phase 3 results published in The Lancet: all endpoints failed, CSF analysis reveals insufficient substantia nigra penetration
|
|
|
|
## References
|
|
|
|
- The Lancet, February 4, 2025: [Exenatide-PD3 Phase 3 Results](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02808-3/fulltext)
|
|
- Parkinson's UK press response, February 2025 |